Published in TZ Latest News
20 December, 2015 by The TZ Newswire Staff
Bionor announces that the HIV ‘Shock & Kill’ trial REDUC with Vacc-4x and romidepsin meets its primary endpoint by significantly reducing latent HIV reservoir and demonstrates control of viral load